Free Trial

Accolade, Inc. (NASDAQ:ACCD) Shares Bought by EntryPoint Capital LLC

Accolade logo with Business Services background
Remove Ads

EntryPoint Capital LLC increased its holdings in Accolade, Inc. (NASDAQ:ACCD - Free Report) by 128.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 83,787 shares of the company's stock after buying an additional 47,113 shares during the period. EntryPoint Capital LLC owned about 0.10% of Accolade worth $287,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of ACCD. Pallas Capital Advisors LLC purchased a new stake in shares of Accolade during the 4th quarter worth $38,000. Mission Creek Capital Partners Inc. purchased a new stake in shares of Accolade during the third quarter valued at about $38,000. Wolverine Trading LLC purchased a new stake in shares of Accolade during the third quarter valued at about $51,000. Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Accolade by 1,144.1% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 20,913 shares of the company's stock valued at $81,000 after buying an additional 19,232 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new position in shares of Accolade in the 3rd quarter worth approximately $96,000. Hedge funds and other institutional investors own 84.99% of the company's stock.

Accolade Stock Performance

Shares of Accolade stock traded up $0.01 during trading on Tuesday, hitting $6.99. 691,838 shares of the company's stock were exchanged, compared to its average volume of 1,403,698. The stock has a market capitalization of $573.13 million, a price-to-earnings ratio of -3.11 and a beta of 2.18. The business has a 50-day simple moving average of $6.94 and a 200-day simple moving average of $5.01. Accolade, Inc. has a 52-week low of $3.08 and a 52-week high of $9.86. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.63 and a current ratio of 2.63.

Remove Ads

Accolade (NASDAQ:ACCD - Get Free Report) last released its quarterly earnings data on Friday, January 10th. The company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.01. Accolade had a negative return on equity of 20.74% and a negative net margin of 40.36%. On average, research analysts forecast that Accolade, Inc. will post -1.2 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ACCD. Canaccord Genuity Group restated a "hold" rating on shares of Accolade in a research note on Wednesday, January 8th. William Blair cut Accolade from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, January 8th. Stifel Nicolaus restated a "hold" rating and set a $7.03 target price (down from $8.00) on shares of Accolade in a research note on Thursday, January 9th. Stephens reiterated an "equal weight" rating and issued a $7.03 price target on shares of Accolade in a research note on Wednesday, February 12th. Finally, Truist Financial downgraded Accolade from a "strong-buy" rating to a "hold" rating in a report on Friday, January 10th. Thirteen analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, Accolade currently has an average rating of "Hold" and a consensus target price of $6.51.

Get Our Latest Stock Report on ACCD

Accolade Profile

(Free Report)

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians.

Featured Stories

Institutional Ownership by Quarter for Accolade (NASDAQ:ACCD)

Should You Invest $1,000 in Accolade Right Now?

Before you consider Accolade, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Accolade wasn't on the list.

While Accolade currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Trump Tariffs Tumble the Stock Market—Here’s How to Protect Your Money
Donald Trump Owns These 7 Stocks, Should You?
 5 Stocks to BUY NOW in April 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads